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Abstract 
Background.  Diabetic macular edema is a significant cause of vision loss, and some patients do 
not respond optimally to existing treatments. This study compared the response of intractable 
diabetic macular edema to intravitreal injection of two anti-VEGF drugs, bevacizumab and 
pegaptanib, both in combination with dexamethasone.  
Methods. A retrospective chart review was conducted to examine patients from an 
ophthalmology practice in one year with diabetic macular edema (DME), recurrent or persistent, 
after focal laser or intravitreal bevacizumab. Patients received bevacizumab/dexamethasone or 
pegaptanib/dexamethasone. Outcome measures were improvement in best corrected visual 
activity (converted to LogMAR) and central macular thickness (CRT). Data on adverse effects 
also were collected.  
Results. The bevacizumab/dexamethasone group included 25 eyes which had pre-treatment 
LogMAR = 0.69 ± 0.49 (mean ± SD) and CRT = 419 ± 131. Post-treatment LogMAR was 0.70 ± 
0.48 and CRT = 377 ± 107. The pegaptanib/dexamethasone group included 14 eyes; pre-
treatment LogMAR = 0.80 ± 0.55 and CRT = 520 ± 108. Post-treatment LogMAR was 0.77 ± 
0.49 and CRT = 46 4 ± 106. Neither treatment had a significant effect on visual acuity. Both 
groups experienced a significant decrease in CRT over time (p = 0.006). The pegaptanib/ 
dexamethasone group had higher CRT at all times (p = 0.020), but the trend in CRT decrease 
was not different between the two groups. Intraocular pressure increased in both groups (p = 
0.038). No other adverse effects were reported.  
Conclusions. Neither bevacizumab/dexamethasone or pegaptanib/dexamethasone significantly 
improved visual acuity in intractable DME, but both decreased central macular thickness. 
Differences in outcome measures between the two treatment groups were not significant. The 
only adverse effect seen was a small increase in intraocular pressure.  
KS J Med 2012; 5(3):83-93. 
 
 
Introduction 
Diabetic retinopathy occurs in 
approximately 29% of persons with diabetes 
mellitus and is severe enough to threaten 
vision among 4.4%.1-3 Diabetic macular 
edema (DME) is a type of retinopathy 
resulting from microvascular damage to 
retinal capillaries, causing breakdown of the 
blood-retinal  barrier  and  allowing  leakage  
 
into the retina.4-5 The resulting edema causes 
damage which can impair visual acuity and 
may result in blindness.6-7 The prevalence of 
DME in diabetic patients varies from 0.9% 
to 29%.8-10 Diabetic retinopathy is the 
leading cause of new onset blindness among 
Americans 20 to 74 years old1 and accounts 
for 4.8% of blindness worldwide.11  
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Treatment for diabetic macular edema is 
complex, controversial, and changing. Laser 
photocoagulation with a focal/grid laser can 
decrease vision loss from DME,12-14 
however, a number of patients fail to 
respond optimally to laser treatment. 
Inflammatory processes may be an 
important component of retinal damage in 
DME,15 which has led to investigation of 
intravitreal corticosteroids as a possible 
treatment.16-18 Studies suggest intravitreal 
dexamethasone improves visual acuity and 
central macular thickness.19,20 Adverse 
effects of intravitreal steroids include 
glaucoma and cataract formation.21-22 
Vascular endothelial growth factor 
(VEGF) is another proposed culprit for 
damage in DME, possibly via increased 
vascular permeability and action as a pro-
inflammatory mediator.23,24  
Bevacizumab (Avastin®) is a 
recombinant humanized antibody that 
targets many VEGF isoforms.25 Intravitreal 
bevacizumab is used off-label for DME.26-31 
Adverse effects of intravitreal bevacizumab 
include anterior chamber reactions from 
injection, increased intraocular pressure, 
endophthalmitis, and rare systemic 
effects.27,32-34  
Pegaptanib (Macugen®) is a pegylated 
aptamer that binds and neutralizes primarily 
the 165-isomer of VEGF. It is approved for 
intravitreal use and is used off-label for 
DME.35-37 Possible adverse effects of 
intravitreal pegaptanib treatment include 
endophthalmitis, retinal detachment, and 
traumatic cataracts.38-40 Research has not 
determined the ideal treatment algorithm for 
diabetic macular edema and the role of anti-
VEGF therapies.41   
No studies have been published 
comparing the efficacy of bevacizumab and 
pegaptanib. These two anti-VEGF agents 
have slightly different structures and 
mechanisms of action and bevacizumab is 
significantly less expensive than pegaptanib. 
Additionally, no published studies have 
examined the efficacy of combination 
therapy with dexamethasone and anti-VEGF 
drugs. This study was designed to compare 
the efficacy of combined intravitreal 
treatments of pegaptanib/dexamethasone 
versus bevacizumab/dexamethasone for 
intractable DME.  
 
Methods 
Participants. A retrospective chart 
review was conducted to examine patients 
with DME in an ophthalmology practice 
who were treated during the 2010 calendar 
year with intravitreal bevacizumab/dexa-
methasone or pegaptanib/dexamethasone. 
Patients who were diagnosed with severe 
DME refractory to other treatments 
including focal laser therapy or intravitreal 
bevacizumab monotherapy had been offered 
combined treatment with intravitreal 
dexamethasone and an anti-VEGF agent.  
Instrument.  Inclusion criteria included a 
diagnosis of diabetic macular edema and an 
intravitreal injection of bevacizumab/dexa-
methasone or pegaptanib/dexamethasone. 
Patients who were lost to follow-up within 
five weeks of treatment were excluded. All 
eyes which met the inclusion/exclusion 
criteria were included in the analysis. The 
following data were collected from patient 
charts: best corrected visual acuity, central 
macular thickness measured by ocular 
coherence tomography (Cirrus HD OCT, 
Carl Zeiss Meditec, Jena, Germany), and 
intraocular pressure (Tono-Pen, Reichert 
Technologies, Depew, New York, USA). 
Data also were collected on patient 
demographics, duration of diabetes, and 
potential adverse effects of the treatment.  
Method of Injections. After informed 
consent, patients were anesthetized with one 
drop of viscous lidocaine and two sets of 
proparacaine ophthalmic drops two minutes 
apart. One minute after the final anesthetic 
drop, subconjunctival injection of 2% 
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lidocaine with epinephrine was performed. 
The eye was prepared with topical 10% 
Betadine®, with application repeated after 
five minutes. Intravitreal injection was 
performed with one of the following agents: 
1.25 mg bevacizumab, 0.03 mg pegaptanib, 
or 0.4 mg dexamethasone. Patients were 
instructed to use polymixin B/trimethoprim 
(Polytrim®) ophthalmic drops four times per 
day for three days before injections and one 
week following injections. Patients treated 
with combined therapy received dexa-
methasone and an anti-VEGF agent via the 
same procedure one to six weeks apart. 
Some patients received additional intra-
vitreal treatments after the conclusion of 
data gathering, depending on response to 
treatment. 
The clinical endpoints of this study were 
best corrected visual acuity (BCVA) and 
central macular thickness (CRT). Visual 
acuity was measured on the Snellen chart 
with the patient’s current prescription and 
with a pinhole. When visual acuity 
improved significantly with the pinhole, this 
measurement was used as BCVA to 
decrease refractive error as a source of 
reduced visual acuity. BCVA was converted 
to the logarithm of the minimum angle of 
resolution (LogMAR) for analysis.42 Central 
macular thickness (microns) was measured 
by ocular coherence tomography; this 
measurement has been shown to correlate 
with visual acuity and severity of 
retinopathy.43 Change in intraocular pressure 
(IOP, measured in mmHg) from baseline to 
extended observation was calculated to 
evaluate a possible adverse effect of therapy. 
Data also were collected regarding other 
possible adverse effects from treatment, as 
well as diabetes history, patient demo-
graphics, and other ocular conditions.  
Analysis. Data were collected on pre-
treatment values, post-treatment values 
measured at the first visit after combined 
treatment (generally within several weeks), 
and extended observation values measured 
at the last visit of the year (an average of 4.5 
months after initial treatment). Changes in 
clinical endpoints were assessed as the 
difference between the baseline measure-
ment and the immediate post-treatment 
measurement. Baseline values for each 
variable were defined as the last measure-
ment collected prior to intravitreal drug 
administration. Repeated measures multi-
variate analysis of variance (rMANOVA) 
was used to determine statistical signi-
ficance after Mauchly’s test of sphericity 
determined the appropriate statistical 
method.44-46 A p-value less than 0.05 was 
considered significant. 
This project was approved by the Human 
Subjects Committee at the University of 
Kansas School of Medicine-Wichita. 
 
Results 
In the 2010 calendar year, 25 eyes were 
treated with combined bevacizumab/ 
dexamethasone administered within a 6-
week period (Table 1). There was large 
variability in this sample; the average pre-
treatment LogMAR was 0.69 ± 0.49 (mean 
± standard deviation) corresponding to an 
average visual acuity of 20/98, and average 
CRT was 419 ± 131 nm before treatment 
(Table 2). Initial post-treatment visual acuity 
improved in eight eyes (32%); decreased 
visual acuity was seen in seven eyes (28%), 
and 10 eyes (40%) experienced no change in 
visual acuity.  
Pegaptanib/dexamethasone was used in 
14 eyes (Table 1). Average pre-treatment 
LogMAR was 0.80 ± 0.55 corresponding to 
an average visual acuity of 20/126; pre-
treatment CRT was 520 ± 108 (Table 2). 
Post-treatment visual acuity improved in 
five eyes (36%), four eyes (29%) 
experienced decreased visual acuity 
following treatment, and five eyes (36%) 
had no change in visual acuity.  
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Table 1. Bevacizumab and pegaptanib treatment groups. 
 Number of 
Eyes 
% Male Mean Age 
(SD) 
 
Mean Duration of 
Diabetes 
(SD) 
Bevacizumab/dexamethasone 25 56% 68 ± 10 16 ± 11 
Pegaptanib/dexamethasone 14 50% 70 ± 11 19 ± 9 
 
Table 2. Values and changes in LogMAR (Logarithm of Minimum Angle of Resolution), Central 
Macular Thickness (CRT), and Intraocular Pressure (IOP). 
 Pre-
treatment 
(Mean ± 
SD) 
Post-
treatment 
(Mean ± 
SD) 
Extended 
observation 
(Mean ± 
SD) 
Mean 
Change in 
LogMAR 
(SD) 
Mean 
Change 
in CRT 
(SD) 
Mean 
Change 
in IOP 
(SD) 
Bevacizumab/ 
dexamethasone 
LogMAR: 
0.69 ± 0.49 
CRT: 419 
± 131 
LogMAR: 
0.70 ± 0.48 
CRT: 377 
± 107 
LogMAR: 
0.70 ± 0.50 
CRT: 391 ± 
127 
0.01 ± 
0.22 
 
-42 ± 96 0.2 ± 3.5 
Pegaptanib/ 
dexamethasone 
LogMAR: 
0.80 ± 0.55 
CRT: 520 
± 108 
LogMAR: 
0.77±0.49 
CRT: 464 
± 106 
LogMAR: 
0.75 ± 0.50 
CRT: 448 ± 
133 
-0.03 ± 
0.17 
-56 ± 85 3.2 ± 6.5 
p-value    0.559 0.750 0.066 
  
The pegaptanib group had increased 
baseline central macular thickness for 
patient age and diabetes duration (Figure 1). 
However, no trend was seen in the LogMAR 
data (Figure 2).  
 
 
 
Figure 1. Graph of Central Macular Thickness over Age (right) and Diabetes Duration (left). 
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Figure 2. Graph of LogMAR over Age (right) and Diabetes Duration (left). 
 
There were subtle differences between 
the LogMAR responses in the two treatment 
groups (Figure 3). Eyes in the pegaptanib 
group had worse baseline visual acuities and 
larger LogMAR values, but visual acuity 
improved over time. In contrast, visual 
acuity in the bevacizumab group remained 
relatively stable. However, these differences 
were not statistically significant. No 
statistically significant change in LogMAR 
between pre-treatment, post-treatment, and 
extended observation occurred in either 
group.  Similarly, there were no differences 
between the pegaptanib/dexamethasone 
group and the bevacizumab/dexamethasone 
group averaged across all observations and 
over time. 
 
 
Figure 3. Graph of LogMAR over Time. 
 
Both groups experienced a significant 
decrease in CRT over time (p = 0.006; 
Figure 4). At all observation points, CRT 
was higher in the pegaptanib group 
compared to the bevacizumab group (p = 
0.020). However, the trends of the change in 
CRT were not significantly different for the 
bevacizumab and pegaptanib groups 
(reflected by the parallel lines in the 
figures). No significant change occurred 
between pre-treatment and post-treatment 
measurements or between post-treatment 
versus extended observation values.  
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Figure 4. Central Macular Thickness over Time. 
 
Intraocular pressure was measured at 
baseline and after extended observation to 
evaluate a possible adverse effect of therapy. 
A significant increase over time occured (p 
= 0.038; Figure 5). No patients in either 
treatment group received a new diagnosis of 
either intraocular hypertension or glaucoma 
during the course of this study. The 
pegaptanib group had a greater increase in 
IOP. The bevacizumab group maintained a 
more stable IOP, although the change was 
similar in trend and direction for the two 
treatment groups. There was no significant 
difference in IOP between the two groups 
when averaged over time.  
Other than the increase in intraocular 
pressure, no other complications were 
reported for any of the eyes in this study. No 
ocular complications such infections or 
retinal detachment occured, and no systemic 
events such as myocardial infarction or 
cerebrovascular events were reported.  
 
 
Figure 5. Graph of Intraocular Pressure over Time. 
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Discussion 
There was no significant effect on visual 
acuity after treatment with either 
bevacizumab/dexamethasone or pegaptanib/ 
dexamethasone, and there was no difference 
in change in visual acuity and central 
macular thickness between the two 
treatment groups. Apparently, neither 
treatment is ideal for refractory diabetic 
macular edema and new therapies are 
needed to improve visual acuity. However, 
patients did not lose visual acuity during the 
study, so the treatments may have prevented 
further vision loss. This is difficult to assess 
in an uncontrolled study. 
Significant decrease in central macular 
thickness occurred in both treatment groups. 
Persistent macular edema can lead to 
significant loss of vision in other ocular 
conditions.47 It is possible that the same may 
hold true for DME, so the reduction in CRT 
could reduce risk of further retinal damage. 
Bevacizumab/dexamethasone and pegap-
tanib/dexamethasone worked equally well to 
decrease CRT. Although pegaptanib has 
more restricted anti-VEGF activity 
compared with bevacizumab (a nonspecific 
anti-VEGF agent), the two compounds had 
similar efficacy.  
Previous studies have shown treatment 
with intravitreal bevacizumab improved 
visual acuity and central macular thickness 
in new-onset DME30-31 as well as DME 
persistent after focal laser therapy.26-28 
Intravitreal pegaptanib also improves visual 
acuity and central macular thickness for 
DME37 and new-onset DME specifically.36 
Our study suggested that the benefits of 
bevacizumab/dexamethasone and pegap-
tanib/dexamethasone are not as striking in 
patients with refractory diabetic macular 
edema who already have failed therapies 
such as intravitreal bevacizumab. Our study 
did not address the benefits of therapy in 
treatment-naïve patients.  
 
 
The pegaptanib group had increased 
CRT for demographic variables and over 
time throughout this study. Although no 
trend was seen for visual acuity, higher CRT 
would be expected in more severe disease 
with increased edema. This may reflect a 
bias in treatment selection; patients with 
more severe DME may have been offered 
pegaptanib more frequently in attempt to 
preserve vision in DME refractory to other 
treatments such as bevacizumab mono-
therapy. 
A small increase in intraocular pressure 
occurred in both the bevacizumab and 
pegaptanib treatment groups. No eyes in this 
study received a diagnosis of glaucoma or 
intraocular hypertension. Although the 
increase in intraocular pressure was 
statistically significant, it is not clear 
whether the small increase is clinically 
significant. The time of intraocular pressure 
measurement was not collected, and the 
normal diurnal variation in intraocular 
pressure could account for the change. 
Elevated intraocular pressure with resulting 
glaucoma has been reported as an important 
adverse effect of intravitreal steroid 
treatment with triamcinolone.21-22 Our study 
suggested that dexamethasone may be less 
problematic than triamcinolone with regard 
to incidence of glaucoma. Further study on 
the long-term effects of treatment may 
clarify this issue. 
Aside from the increase in intraocular 
pressure, no other ocular or systemic 
adverse effects were seen. There were no 
reports of endophthalmitis following 
intravitreal injection. This is noteworthy as 
there are reports of endophthalmitis 
following intravitreal bevacizumab, likely 
due to processing by compounding 
pharmacies.32,33,48 While all data were 
collected from ophthalmology charts to 
evaluate  adverse   effects,   complete  health 
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records were not available. Data on systemic 
events may not have been available if events 
were not communicated to the ophthal-
mologist.  
Limitations. This was a small 
retrospective pilot study with several 
inherent limitations. This study did not 
include a control group, and patients were 
not randomized into treatment groups. It 
may have been underpowered to detect 
subtle differences. Pertinent data were 
unavailable on many patients. For example, 
visual acuity was measured with a patient's 
current prescription but refraction was not 
optimized for the patient at the time of 
testing. Complete health records were not 
available, and background information on 
diabetes such as hemoglobin A1c level was 
not recorded for many patients, limiting the 
ability to judge if the two treatment groups 
were initially equivalent. 
Patients were treated with alternating 
injections of dexamethasone and an anti-
VEGF agent. The influence of the steroid 
treatment may make it more difficult to 
compare pegaptanib to bevacizumab. This 
study examined patients over the course of 
one calendar year; extension of this study to 
examine a longer time frame would give a 
clearer picture of the duration of treatment 
effects as well as any adverse effects. This 
study was limited to patients with severe 
DME which previously had proved recurrent 
or refractory to therapy. These results cannot 
be generalized to draw conclusions about the 
benefit of bevacizumab, pegaptanib, or 
dexamethasone for new onset diabetic 
macular edema.  
 
Conclusions 
Patients with intractable diabetic 
macular edema did not experience signi-
ficant improvement in visual acuity after 
therapy with bevacizumab/dexamethasone 
or pegaptanib/dexamethasone. However, 
decreased central macular thickness was 
seen after both therapies. There was no 
significant difference in outcome measures 
between the two treatment groups. 
Intraocular pressure increased slightly after 
treatment, but no other adverse effects were 
experienced by any eyes in this study. 
Further study is needed to confirm these 
conclusions, ideally a large randomized, 
blinded, controlled trial to compare the 
efficacy of pegaptanib and bevacizumab. 
Study also is needed to examine the effects 
of these treatments for new-onset DME, to 
define the long-term effects of treatment, 
and to quantify the effects of dexamethasone 
when combined with either pegaptanib or 
bevacizumab. Research is needed on new 
therapies for refractory diabetic macular 
edema which would improve visual acuity 
as well as preventing further damage.  
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